PA-CLINICAL-INK
Clinical Ink today announced it ranked on the Deloitte Technology Fast 500 ™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 27th year. Clinical Ink grew 293% during this period.
Clinical Ink’s Chief Executive Officer, Ed Seguine , credits the 293% growth to expertise in highly complex therapeutic areas (Alzheimer's, Lupus, COVID) and novel execution models such as decentralized and remote trials. Seguine stated, “Clinical Ink has consistently delivered results for our customers and earned their trust. We’ve always been at the forefront of innovation with technologies that simplify and accelerate complex clinical trial activities. The recent acquisition of Digital Artefacts will drive future growth as we lead the next wave of innovation by simplifying the adoption of digital endpoints.”
About the 2021 Deloitte Technology Fast 500™
Now in its 27th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2017 to 2020.
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.
Clinical Ink ranked No. 393 on the Deloitte Technology Fast 500 ™.
About Clinical Ink
Clinical Ink , a global clinical technology company, offers data certainty from source to submission. Our Lunexis™ eSource clinical technology and configurable direct data capture, eCOA, patient engagement, telehealth, eConsent, and instrumented data collection modules provide a suite of solutions for capturing and integrating electronic data from sites, clinicians, caregivers, and patients at its source. Clinical Ink’s therapeutic-area-specific approach to study design and data capture – with specific expertise in neurocognitive testing – enables more precise scales for cognitive and human factors assessments, including performance, behavior, movement, and all real-world activity.
About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117006158/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 202515.10.2025 22:57:00 CEST | Press release
15 abstracts spanning advancements in early detection of recurrence, tumor profiling, and therapy response monitoringPresentations highlight the power of Guardant Health’s blood-based assays to reduce treatment burden and improve disease monitoring across multiple cancer types Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that new data from across its oncology portfolio will be presented in 15 accepted abstracts at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany. These presentations span the cancer care treatment continuum, from minimal residual disease (MRD) detection and recurrence monitoring to advanced-stage tumor profiling and therapy response assessment. Guardant Health’s accepted abstracts span multiple tumor types, including lung, colorectal, breast, head and neck, and cancers of unknown primary. Together, they underscore the company’s commitment to harnessing cutting-edge
Greenland Resources Signs Mandate Agreement With European Bank15.10.2025 21:06:00 CEST | Press release
Greenland Resources A/S, a fully owned Greenlandic subsidiary of Greenland Resources Inc. (Cboe CA: MOLY | FSE: M0LY) (“Greenland Resources” or the “Company”) is pleased to announce the Company has signed a mandate letter with a major German Bank (the “Bank”) to act as the Export Credit Agency (“ECA”) Coordinator for the Project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015159644/en/ The ECA Coordinator role covers the relevant tasks up to debt financial close. The Bank has extensive experience in acting as the ECAs Coordinator in project financings worldwide, as well as being one of Europe’s most prestigious institutions. The Bank will now be in a position to start working with some of the ECA’s discussed in previous press releases (primarily EKN, Finnvera, and EIFO). The Company’s debt part of the Capex is around US$750 million. Mandating the Bank complements the Company’s strategy to increase EU and specifically
Interactive Brokers Launches Ask IBKR: AI Tool Delivers Instant Portfolio Answers15.10.2025 16:00:00 CEST | Press release
New Natural Language Interface Helps Clients Analyze Holdings, Performance, and Allocation in Seconds Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the launch of Ask IBKR, an AI-powered tool that delivers instant portfolio insights through natural language queries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015991473/en/ “With Ask IBKR, we’re introducing a natural language-based way for investors to interact with their portfolio data,” said Milan Galik, Chief Executive Officer at Interactive Brokers. “Instead of navigating across screens, clients can simply ask, ‘What sector am I underweight compared to the S&P 500?’ and get an instant, visualized answer.” Categories of queries include: Portfolio Metrics: Compare performance against benchmarks, identify valuation changes over time, and highlight periods of outperformance or underperformance Allocation Analysis: Analyze sect
Multiply Group Announces Plans to Acquire 2PointZero and Ghitha Holding via Share Swap15.10.2025 15:36:00 CEST | Press release
The proposed acquisition forms part of Multiply Group’s broader strategy to build scale, enhance portfolio synergies, and drive long-term value.2PointZero brings scalable assets across energy, mining and financial services, while Ghitha Holding contributes a diversified food and agriculture platform.The transaction remains subject to shareholder and regulatory approvals, with further details to be announced upon completion of the review process. Multiply Group (ADX: MULTIPLY), the Abu Dhabi-based investment holding company that invests in and operates businesses globally, today announced that its Board has approved a proposal to acquire 2PointZero and Ghitha Holding through a share swap transaction. Under the proposed terms, Multiply Group would offer shares to acquire 2PointZero and Ghitha Holding, followed by the issuance of new shares to complete the transaction. The transaction is currently under review and remains subject to shareholder and regulatory approvals. 2PointZero is a tr
Svante Hails Nobel Prize in Chemistry, Validating Metal-Organic Framework Technology is Critical for Commercial Carbon Capture15.10.2025 15:30:00 CEST | Press release
The Nobel Prize for Chemistry has awarded scientists for their work in metal-organic frameworks (MOFs), for their high capacity and selectivity for captured gases, including CO2. The CALF-20 MOF used in Svante’s filters for carbon capture and removal, was highlighted in the award announcement. Svante, a leader in solid sorbent-based carbon capture and removal filter technology, celebrated the announcement of the 2025 Nobel Prize in Chemistry last week, which honored scientists Susumu Kitagawa, Richard Robson and Omar Yaghi for their groundbreaking work in the metal-organic framework (MOF) field. The Royal Swedish Academy of Sciences awarded the prize for the development of MOFs, citing their "enormous potential" and unique molecular architecture that creates spacious, porous materials capable of capturing and storing specific substances, including carbon dioxide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015855374/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom